3,006
Views
3
CrossRef citations to date
0
Altmetric
Articles

Bladder cancer recurrence in papillary urothelial neoplasm of low malignant potential (PUNLMP) compared to G1 WHO 1999: a population-based study

ORCID Icon, , , , , , , , , , & ORCID Icon show all
Pages 14-18 | Received 14 Jun 2021, Accepted 28 Sep 2021, Published online: 08 Oct 2021

References

  • MacLennan GT, Kirkali Z, Cheng L. Histologic grading of noninvasive papillary urothelial neoplasms. Eur Urol. 2007;51(4):889–897; discussion 897–898.
  • van Rhijn BW, Burger M, Lotan Y, et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol. 2009;56(3):430–442.
  • Jones TD, Cheng L. Papillary urothelial neoplasm of low malignant potential: evolving terminology and concepts. J Urol. 2006;175(6):1995–2003.
  • Hofmann TK-C, Hartmann R, Stöhr A, et al. Clinical implications of the 2004 WHO histological classification on non-invasive tumours of the urinary bladder. EAU-EBU Update Series. 2006;4(3):83–95.
  • Hentschel AE, van Rhijn BWG, Brundl J, et al. Papillary urothelial neoplasm of low malignant potential (PUN-LMP): still a meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019? Urol Oncol. 2020;38(5):440–448.
  • Sylvester RJ, Rodriguez O, Hernandez V, et al. European Association of Urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC guidelines panel. Eur Urol. 2021;79(4):480–488.
  • Haggstrom C, Liedberg F, Hagberg O, et al. Cohort profile: the Swedish National Register of Urinary Bladder Cancer (SNRUBC) and the bladder cancer data base Sweden (BladderBaSe). BMJ Open. 2017;7(9):e016606.
  • Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
  • R Core Team 2020. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing. Available from: https://www.R-project.org/
  • Oosterhuis JW, Schapers RF, Janssen-Heijnen ML, et al. Histological grading of papillary urothelial carcinoma of the bladder: prognostic value of the 1998 WHO/ISUP classification system and comparison with conventional grading systems. J Clin Pathol. 2002;55(12):900–905.
  • Cheng L, Neumann RM, Bostwick DG. Papillary urothelial neoplasms of low malignant potential. Clinical and biologic implications. Cancer. 1999;86(10):2102–2108.
  • Holmang S, Andius P, Hedelin H, et al. Stage progression in ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy. J Urol. 2001;165(4):1124–1128. discussion 1128–1130.
  • Holmang S, Hedelin H, Anderstrom C, et al. Recurrence and progression in low-grade papillary urothelial tumors. J Urol. 1999;162(3 Part 1):702–707.
  • Fujii Y, Kawakami S, Koga F, et al. Long-term outcome of bladder papillary urothelial neoplasms of low malignant potential. BJU Int. 2003;92(6):559–562.
  • van Rhijn BWG, Hentschel AE, Brundl J, et al. Prognostic value of the WHO1973 and WHO2004/2016 classification systems for grade in primary Ta/T1 non-muscle-invasive bladder cancer: a multicenter European Association of Urology non-muscle-invasive bladder cancer guidelines panel study. Eur Urol Oncol. 2021;4(2):182–191.
  • Liedberg F, Lauss M, Patschan O, et al. The importance of being grade 3: WHO 1999 versus WHO 2004 pathologic grading. Eur Urol. 2012;62(4):620–623.
  • Malmstrom PU. Cystoscopic surveillance of patients with non-muscle-invasive bladder cancer revisited. Scand J Urol. 2020:54(5):364–366.